Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells

  • Authors:
    • Paul Thelen
    • Stefan Schweyer
    • Bernhard Hemmerlein
    • Wolfgang Wuttke
    • Florian Seseke
    • Rolf-Hermann Ringert
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/ijo.24.1.25
  • Pages: 25-31
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pathogenesis of prostate cancer is paralleled by aberrant transcriptional regulation which involves gene silencing by histone deacetylases. In cancer cells, inhibitors of histone deacetylases such as valproic acid can act as differentiation agents which relieve pro-apoptotic factors from transcriptional repression. We investigated the potential of the well-tolerated anticonvulsant valproic acid in prostate cancer cell line LNCaP and analyzed the activation of pro-apoptotic factors and resulting apoptosis. We used real time RT-PCR to quantify the mRNA expression of prostate-specific antigen, prostate-derived Ets transcription factor, tissue inhibitor of matrix metalloproteinase-3 and insulin-like growth factor binding protein-3. An automated sandwich-ELISA was used to measure secretion of prostate-specific antigen in conditioned cell culture media of LNCaP prostate cancer cells. Apoptotic cells were detected cytochemically and by applying immunocytochemistry. Activity of histone deacetylases in nuclear extracts was measured with a colorimetric assay kit. Valproic acid treatment caused a marked inhibition of histone deacetylases activity. Expression of prostate-derived Ets transcription factor and consequently prostate-specific antigen were down-regulated to basal levels in LNCaP cells. Pro-apoptotic factor caspase-3, tissue inhibitor of matrix metalloproteinase-3 and insulin-like growth factor binding protein-3 were up-regulated resulting in apoptosis of tumor cells. Valproic acid mediates marked effects on the expression of genes relevant in proliferation and apoptosis. Our study provides strong evidence that prostate cancer may benefit particularly from anti-proliferative stimuli from this well established drug.

Related Articles

Journal Cover

January 2004
Volume 24 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., & Ringert, R. (2004). Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. International Journal of Oncology, 24, 25-31. https://doi.org/10.3892/ijo.24.1.25
MLA
Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., Ringert, R."Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells". International Journal of Oncology 24.1 (2004): 25-31.
Chicago
Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., Ringert, R."Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells". International Journal of Oncology 24, no. 1 (2004): 25-31. https://doi.org/10.3892/ijo.24.1.25